Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233

Journal of Clinical Oncology

Volumn 32, Issue 34, 2014, Pages 3801-3809

  Mak, Raymond H ^a   Hunt, Daniel ^c   Shipley, William U ^b   Efstathiou, Jason A ^b   Tester, William J ^d   Hagan, Michael P ^e   Kaufman, Donald S ^b   Heney, Niall M ^b   Zietman, Anthony L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d ALBERT EINSTEIN MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER; CARCINOMA; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE FREE SURVIVAL; META ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SALVAGE THERAPY; SECONDARY; SMOOTH MUSCLE; SURGERY; TIME; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; ORGAN SPARING TREATMENTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84912114298     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.5548     Document Type: Article

References (34)

1. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001
2. Dalbagni G, Genega E, Hashibe M, et al: Cystectomy for bladder cancer: A contemporary series. J Urol 165:1111-1116, 2001
3. Zehnder P, Studer UE, Skinner EC, et al: Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study. J Urol 186:1261-1268, 2011
4. Madersbacher S, Hochreiter W, Burkhard F, et al: Radical cystectomy for bladder cancer today: A homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690-696, 2003
5. Hautmann RE, Gschwend JE, de Petriconi RC, et al: Cystectomy for transitional cell carcinoma of the bladder: Results of a surgery only series in the neobladder era. J Urol 176:486-492, 2006
6. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
7. Munro NP, Sundaram SK, Weston PM, et al: A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 77:119-124, 2010
8. Kotwal S, Choudhury A, Johnston C, et al: Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 70:456-463, 2008
9. Shipley WU, Kaufman DS, Zehr E, et al: Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60:62-67, 2002
10. Rödel C, Grabenbauer GG, Kühn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20:3061-3071, 2002
11. Efstathiou JA, Spiegel DY, Shipley WU, et al: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 61:705-711, 2012
12. Weiss C, Engehausen DG, Krause FS, et al: Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68:1072-1080, 2007
13. Efstathiou JA, Bae K, Shipley WU, et al: Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055-4061, 2009
14. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119-126, 1996
15. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576-3583, 1998
16. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471-476, 2000
17. Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665-672, 2003
18. Kaufman DS, Winter KA, Shipley WU, et al: Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833-837, 2009
19. Mitin T, Hunt D, Shipley WU, et al: Transurethral surgery and twice-daily radiation plus paclitaxelcisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): A randomised multicentre phase 2 trial. Lancet Oncol 14:863-872, 2013
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:447-457, 1958
21. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1143, 1988
22. Zietman AL, Sacco D, Skowronski U, et al: Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 170:1772-1776, 2003
23. Henningsohn L, Steven K, Kallestrup EB, et al: Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 168:168-174, 2002
24. Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al: Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: Results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 79:172-178, 2011
25. Caffo O, Fellin G, Graffer U, et al: Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self-administered questionnaire. Cancer 78:1089-1097, 1996
26. Eswara JR, Efstathiou JA, Heney NM, et al: Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol 187:463-468, 2012
27. Gray PJ, Fedewa SA, Shipley WU, et al: Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol 31, 2013 (suppl 6; abstr 248)
28. Huddart RA, Hall E, Lewis R, et al: Life and death of SPARE (selective bladder preservation against radical excision): Reflections on why the SPARE trial closed. BJU Int 106:753-755, 2010
29. Gakis G, Efstathiou J, Lerner SP, et al: ICUDEAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63:45-57, 2013
30. Shipley WU, Efstathiou JA: Radiation-based bladder preserving strategies: Radiation alone or combined with other modalities, in Soloway M, Khoury S (eds): Bladder Cancer: International Consultation on Bladder Cancer-Vienna (ed 2). Paris, France, International Consultation on Urological Diseases-European Association of Urology, 2012, pp 316-326
31. James ND, Hussain SA, Hall E, et al: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477-1488, 2012
32. Clark PE, Agarwal N, Biagioli MC, et al: Bladder cancer. J Natl Compr Canc Netw 11:446-475, 2013
33. Hoskin PJ, Rojas AM, Bentzen SM, et al: Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912-4918, 2010
34. Choudhury A, Nelson LD, Teo MT, et al: MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 70:7017-7026, 2010